Search Result "aromatase inhibitor-associated bone loss."
Therapeutic Options for the Management of Aromatase Inhibitor-Associated Bone Loss
Journal: Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume: 22 Issue: 3 Year: 2022 Page: 259-273
Author(s): Pietro Castellino,Rosario Rapisarda,Anastasia Xourafa,Agostino Gaudio
Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Journal: Current Medicinal Chemistry
Volume: 15 Issue: 3 Year: 2008 Page: 284-304
Author(s): P. Valverde
Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 17 Issue: 13 Year: 2017 Page: 1805-1813
Author(s): K.J. Baatjes,M. Conradie,J.P. Apffelstaedt,M.J. Kotze
CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up
Journal: Current Pharmaceutical Design
Volume: 26 Issue: 46 Year: 2020 Page: 6007-6012
Author(s): Karin Baatjes,Armand Peeters,Micheal McCaul,Maria M. Conradie,Justus Apffelstaedt,Magda Conradie,Maritha J. Kotze
Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Journal: Current Medicinal Chemistry - Anti-Cancer Agents
Volume: 4 Issue: 6 Year: 2004 Page: 523-534
Author(s): J. Narashimamurthy, A. Raghu Ram Rao, G. Narahari Sastry
Natural Products as Aromatase Inhibitors
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 8 Issue: 6 Year: 2008 Page: 646-682
Author(s): Marcy J. Balunas, Bin Su, Robert W. Brueggemeier, A. Douglas Kinghorn
Skeletal Effects of Drugs to Treat Cancer
Journal: Current Drug Safety
Volume: 3 Issue: 3 Year: 2008 Page: 173-177
Author(s): Peter Vestergaard
Interrelationships Between Cyclooxygenases and Aromatase: Unraveling the Relevance of Cyclooxygenase Inhibitors in Breast Cancer
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 6 Issue: 3 Year: 2006 Page: 221-232
Author(s): Edgar S. Diaz-Cruz, Robert W. Brueggemeier
Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation:Is Prompt Antiresorptive Therapy Always Recommended, Even When the Risk of Fracture Seems Low? A Case Report
Journal: Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume: 21 Issue: 12 Year: 2021 Page: 2303-2306
Author(s): Giangiacomo Osella,Soraya Puglisi,Anna Alì,Giuseppe Reimondo,Massimo Terzolo
Bisphosphonates as Treatment of Bone Metastases
Journal: Current Pharmaceutical Design
Volume: 16 Issue: 1 Year: 2010 Page: 1262-1271
Author(s): Ingunn Holen, Robert E. Coleman